Search Results

You are looking at 151 - 160 of 2,911 items for :

  • Refine by Access: All x
Clear All
Full access

QIM22-206: Physical Therapy Outcomes in Oncology Multidisciplinary Clinics

Cari Utendorf, Amy Compston, and Brittany Knauss

intervention to prevent further functional decline throughout cancer treatment. Methods : Physical therapy (PT) is integrated in the cancer-aging resiliency and pancreatic clinics. A PT evaluation is completed, with the following outcomes obtained as listed in

Full access

Prognostic and Predictive Markers for Patients With Anal Cancer

Emma B. Holliday, Arjun Peddireddy, and Van K. Morris

States. 3 Updated therapeutic approaches for patients with nonmetastatic and metastatic SCCA alike are needed to improve survival outcomes. Concurrent chemoradiation has remained the steadfast treatment for locoregional SCCA for the past half

Full access

Neoadjuvant or Adjuvant Chemotherapy Plus Concurrent CRT Versus Concurrent CRT Alone in the Treatment of Nasopharyngeal Carcinoma: A Study Based on EBV DNA

Li-Ting Liu, Qiu-Yan Chen, Lin-Quan Tang, Shan-Shan Guo, Ling Guo, Hao-Yuan Mo, Yang Li, Qing-Nan Tang, Xue-Song Sun, Yu-Jing Liang, Chong Zhao, Xiang Guo, Chao-Nan Qian, Mu-Sheng Zeng, Jin-Xin Bei, Ming-Huang Hong, Jian-Yong Shao, Ying Sun, Jun Ma, and Hai-Qiang Mai

classifications have markedly different survival outcomes. Infection with Epstein-Barr virus (EBV) is strongly linked to NPC. 13 , 14 Previous studies have shown that patients with high levels of pretreatment plasma EBV DNA have higher rates of distant relapse

Full access

Relationship Between Perceptions of Treatment Goals and Psychological Distress in Patients With Advanced Cancer

Areej El-Jawahri, Deborah Forst, Alyssa Fenech, Keri O. Brenner, Amanda L. Jankowski, Lauren Waldman, Isabella Sereno, Ryan Nipp, Joseph A. Greer, Lara Traeger, Vicki Jackson, and Jennifer Temel

their cancer. Figure 1. Patients’ perceptions of their treatment goal and of their oncologist’s goal. Association Between Patients’ Perceptions of Treatment Goals and Patient-Reported Outcomes Figures 2 and 3 depict the rates of clinically significant

Full access

Neuroendocrine Prostate Cancer: Subtypes, Biology, and Clinical Outcomes

Rahul Aggarwal, Tian Zhang, Eric J. Small, and Andrew J. Armstrong

and outcomes of NEPC Outline treatment options for patients with NEPC Neuroendocrine prostate cancer (NEPC) is a lethal form of prostate cancer, with most patients dying within 1 to 2 years of diagnosis. 1 , 2 Pure localized small cell carcinoma

Full access

Immune Checkpoint Inhibitor Use in Solid Organ Transplant Recipients: A Systematic Review

Andrew J. Portuguese, Scott S. Tykodi, Christopher D. Blosser, Ted A. Gooley, John A. Thompson, and Evan T. Hall

are now eligible for treatment with ICIs. 8 Due to the need for chronic immunosuppressive therapy, SOTRs with cancer have been consistently excluded from clinical trials with ICIs. 9 – 16 Thus, clinical outcomes for cancers arising in SOTRs treated

Full access

Neoadjuvant Therapy for Rectal Cancer Affects Lymph Node Yield and Status Without Clear Implications on Outcome: The Case for Eliminating a Metric and Using Preoperative Staging to Guide Therapy

Sherif R. Z. Abdel-Misih, Lai Wei, Al B. Benson III, Steven Cohen, Lily Lai, John Skibber, Neal Wilkinson, Martin Weiser, Deborah Schrag, and Tanios Bekaii-Saab

Background Nodal status has long been considered a key pathologic factor in cancer management and care. Previous studies have demonstrated an association between lymph node yield and status with regard to patient outcomes in colorectal cancer

Full access

Benefit of Postoperative Radiotherapy for Patients With Nonmetastatic Adrenocortical Carcinoma: A Population-Based Analysis

Kan Wu, Xu Liu, Zhihong Liu, Yiping Lu, Xianding Wang, and Xiang Li

recurrence, leading to a poor prognosis. 4 Therefore, there is an urgent need for adjuvant treatment intensification to prevent disease recurrence and improve survival outcomes. Currently, mitotane monotherapy, cytotoxic drugs, and radiotherapy (RT) are

Full access

Enrollment Criteria Controversies for Active Surveillance and Triggers for Conversion to Treatment in Prostate Cancer

David D. Buethe and Julio Pow-Sang

remains to optimize the criteria that qualify a man as either low risk or very low risk, and to establish standardized criteria defining disease progression. Further, there is a paucity of reports on the long-term outcomes of men electing to delay or forgo

Full access

Metastasis and Mortality in Men With Low- and Intermediate-Risk Prostate Cancer on Active Surveillance

P. Travis Courtney, Rishi Deka, Nikhil V. Kotha, Daniel R. Cherry, Mia A. Salans, Tyler J. Nelson, Abhishek Kumar, Elaine Luterstein, Anthony T. Yip, Vinit Nalawade, J. Kellogg Parsons, A. Karim Kader, Tyler F. Stewart, and Brent S. Rose

studies of AS in intermediate-risk disease have been limited by small sample sizes, short follow-up, and lack of definitive clinical outcomes, including metastasis and prostate cancer–specific mortality (PCSM). 5 – 12 Nevertheless, the use of AS in